FDA reviewing safety of abortion drug mifepristone
The retrospective review covers hundreds of thousands of cases and could lead to limits on telehealth, mail delivery and prescribing, officials said.
- On Thursday, the Food and Drug Administration launched a safety study of the abortion pill mifepristone, a move that could allow the Trump administration to restrict the medication's distribution despite the Supreme Court's recent restoration of mail-access.
- Health and Human Services Secretary Robert F. Kennedy Jr. previously announced plans to review safety, responding to pressure from anti-abortion groups and an October deadline set by a Louisiana federal court.
- More than 7.5 million women have used the medication over 25 years, with the American Medical Women's Association reporting fewer than 0.5 percent of patients experience serious adverse reactions, making it safer than ibuprofen.
- With preliminary results expected in July, the agency may meet its October deadline, potentially enabling officials to block distribution by mail or telehealth, though the FDA is unlikely to ban the drug outright.
23 Articles
23 Articles
FDA Launches Review of Abortion Pill
The Food and Drug Administration (FDA) launched a safety review of the abortion pill mifepristone. The news, reported by The Wall Street Journal, comes as pro-life groups have urged the Trump administration to take action on the drug for months. “We already know chemical abortions kill babies and endanger women,” Sen. Bill Cassidy (R-LA) told the outlet. “The Trump administration needs to stop dragging their feet and immediately reinstate the in…
FDA Launches Study on Safety of Abortion Pill
At long last, the Food and Drug Administration (FDA) has announced plans to study the safety of the drug mifepristone, better known as the “abortion pill.” The decision comes years after President Joe Biden and his administration authorized the drug to be distributed via telehealth appointments and through the mail. Previously, any woman who sought the prescription pharmaceutical was required to see a doctor in-person. Advocates for the abortion…
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D24&w=64&q=75){kind=small}
FDA Opens New Review Of Mifepristone Safety As Trump Administration Weighs Abortion Pill Restrictions
The Food and Drug Administration has begun a new review of mifepristone safety, with officials expected to examine telehealth prescribing, mail-order distribution and Biden-era changes ... The post FDA Opens New Review Of Mifepristone Safety As Trump Administration Weighs Abortion Pill Restrictions first appeared on [your]NEWS.
Coverage Details
Bias Distribution
- 42% of the sources lean Right
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
